OssDsign’s first quarter results to be presented live

OssDsign AB (publ) (“OssDsign” or the “Company”) will present their upcoming Q1 report live via Finewire TV Webcast 

OssDsign will be publishing the interim report for the first quarter on Wednesday May 13th at 08:00 CET. Later on the same day, the results will be presented live (in Swedish) by CEO Anders Lundqvist via a webcast in cooperation with Finwire Media. The webcast, which will run from 13:00 CET on May 13th, can be followed via the link https://www.finwire.tv/webcast/ossdsign/q1/  where it also is possible to already now submit questions.  

 

For further information, please contact:

Anders Lundqvist, CEO, OssDsign AB
Tel: +46 73 206 98 08
Email: al@ossdsign.com

Certified Adviser:
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.

About OssDsign
OssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.

Tags:

About Us

OssDsign is a Swedish medical technology company that develops and manufactures regenerative implants for improved healing of bone defects. Providing neuro and plastic surgeons with innovative implants, OssDsign improves the outcome for patients with severe cranial and facial defects worldwide. By combining clinical knowledge with proprietary technology, OssDsign manufactures and sells a growing range of patient-specific solutions for treating cranial defects and facial reconstruction. OssDsign's technology is the result of collaboration between clinical researchers at Karolinska University Hospital in Stockholm and material scientists at the Ångström Laboratory at Uppsala University.